Bristol’s image with investors
Exec VP Donald Hayden presented on behalf of Bristol at the Deutsche Bank healthcare conference in Baltimore May 8, where he received a warm response. Hayden, who was given operational responsibility for the U.S. Rx business in April, noted that he has been afforded ample latitude to make the changes he feels are necessary to put the business back on track...
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.